REDWOOD CITY, Calif.--(BUSINESS WIRE)--Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that MedStar Health, a not-for-profit health system of 4,300 affiliated physicians and 10 hospitals, ambulatory care and urgent care centers, has introduced the Sonata® Procedure in the Maryland and Washington, D.C. area. The first case at MedStar Health was performed by Vadim Morozov, M.D., the Director of the American Academy of Gynecologic Laparoscopists (AAGL) Fellowship in Minimally Invasive Gynecologic Surgery at MedStar Washington Hospital Center.
Fibroids are benign growths in or around the uterus, with about 70 percent of white women and more than 80 percent of black women having uterine fibroids before the age of 50. Uterine fibroids may cause significant and debilitating symptoms, including heavy menstrual bleeding. Symptoms may worsen over time if fibroids are left untreated, which leads to more than two million women in the U.S. undergoing treatment for uterine fibroids each year.
“Invasive surgery can be a major deterrent to women who would otherwise seek treatment,” said Chris Owens, President and CEO of Gynesonics. “We are committed to making Sonata available to all women who suffer from symptomatic uterine fibroids. This acknowledgment of the clinical importance of Sonata by Dr. Morozov and MedStar Health is important for patients in the Washington D.C./Maryland area. We are excited to be accelerating our commercial efforts and launch of the Sonata System across the United States and globally.”
The Sonata procedure offers women with symptomatic uterine fibroids an option that is incision-free, has a quick recovery with excellent reduction in heavy menstrual bleeding symptoms, and provides an option to avoid invasive surgery. Sonata uses a unique intrauterine ultrasound handpiece to locate and target the individual fibroids. Radiofrequency energy is delivered to shrink the fibroid and reduce symptoms. The Sonata Treatment is a breakthrough alternative to hysterectomy and myomectomy, and can treat a wide range of fibroid types, sizes, and locations. The fibroids are treated from inside the uterus, so the Sonata Treatment requires no incisions, no tissue is surgically removed, and the uterus is preserved. Clinical studies demonstrate that nearly 90 percent of women showed a reduction in menstrual bleeding at three months and 95 percent had a reduction in bleeding at 12 months. Additionally, 50 percent of women returned to normal activities the next day.
For more information on the Sonata Treatment and to watch patient testimonials, please visit www.sonatatreatment.com.
About Sonata System
The Sonata System uses radiofrequency energy to ablate fibroids under real time sonography guidance from within the uterine cavity, utilizing the first and only intrauterine ultrasound transducer. The System includes a proprietary graphical user interface (SMART Guide), enabling the operator to target fibroids and optimize treatment. The Sonata system provides incision-free transcervical access for a uterus-preserving fibroid treatment. This intrauterine approach is designed to avoid the peritoneal cavity. The Sonata System is CE marked and is approved for sale in the European Union and the United States.
Gynesonics is a women’s healthcare company focused on advancing women’s health, by developing minimally invasive, incision-free, uterus-preserving, transcervical technologies for diagnostic and therapeutic applications. Gynesonics has developed the Sonata System for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids. Gynesonics headquarters is in Redwood City, CA. For more information, go to www.gynesonics.com.